RecruitingPhase 1NCT07096869

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

Studying Chronic bilirubin encephalopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Intervention
Paclitaxel protein-bound particles for injectable suspension (albumin-bound)(drug)
Enrollment
28 target
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07096869 on ClinicalTrials.gov

Other trials for Chronic bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic bilirubin encephalopathy

← Back to all trials